HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand

Hematology Journal

Volumn 1, Issue 6, 2000, Pages 403-410

  Gillespie, Geraldine ^a   Mutis, Tuna ^b   Schrama, Ellen ^b   Kamp, Janine ^b   Esendam, Bennie ^b   Falkenburg, J H Frederik ^b   Goulmy, Els ^b   Moss, Paul ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adoptive immunotherapy; Cytotoxic T cells; MHC peptide tetramers; Minor histocompatibility antigens

Indexed keywords

BIOPOLYMER; HA 1 ANTIGEN; HA 2 ANTIGEN; HA-1 ANTIGEN; HA-2 ANTIGEN; LIGAND; MINOR HISTOCOMPATIBILITY ANTIGEN; OLIGOPEPTIDE; PEPTIDE FRAGMENT; TUMOR PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CELL CULTURE; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; LEUKEMIA; SYNTHESIS;

ANTIGEN PRESENTATION; BIOPOLYMERS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; LIGANDS; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASM PROTEINS; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034584608     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200065     Document Type: Article

References (23)

1. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunological Reviews 157: 125, 1997.
2. den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF, Engelhard VH, Goulmy E. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279: 1054, 1998.
3. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout J-W, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268: 1476, 1995.
4. de Bueger M, Bakker A, van Rood JJ, van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. Journal of Immunology 149: 1788, 1992.
5. Falkenburg JH, Goselink HM, van der Harst D, Luxemburg-Heijs SA, Kooy-Winkelarr YM, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. Journal of Experimental Medicine 174: 27, 1991.
6. van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YM, Luxemburg-Heijs SA, Goselink HM, Brand A. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83: 1060, 1994.
7. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 93: 2336, 1999.
8. Speiser DE, Kyburz D, Stubi U, Hengartner H, Zinkernagel RM. Discrepancy between in vitro measurable and in vivo neutralizing cytotoxic T-cell reactivities. Low T-cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. Journal of Immunology 49: 972, 1992.
9. Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94, 1996.
10. + T-cells: a reevaluation of bystander activation during viral infection. Immunity 8: 177, 1998.
11. + T-cells during the primary immune response to Epstein-Barr virus in vivo. Journal of Experimental Medicine 187: 1395, 1988.
12. + T-cells in individuals receiving highly active antiretroviral therapy (HAART). Journal of Immunology 162: 178, 1999.
13. Crawford F, Kozono H, White J, Marrack P, Kappler J. Detection of antigen-specific T-cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8: 675, 1988.
14. Mutis T, Gillespie G, Schrama E, Falkenburg JHF, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nature Medicine 5: 839, 1999.
15. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHA tetramers. Journal of Immunology 162: 2227, 1999.
16. Savage PA, Boniface JJ, Davis MM. A kinetic basis for T-cell receptor repertoire selection during an immense response. Immunity 10: 485, 1999.
17. Busch DH, Pamer EG. T-cell affinity maturation by selective expansion during infection. Journal of Experimental Medicine 189: 701, 1999.
18. Plebanski M, Allsopp CE, Aidoo M, Reyburn H, Hill AV. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human periperal blood. European Journal of Immunology 25: 1783, 1995.
19. + T-cell responses against cancer-associated MUC1 peptide epitopes. International Immunology 10: 1907, 1998.
20. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. Journal of Immunology 161: 5607, 1998.
21. Wong C, Morse M, Nair SK. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. Journal of Immunotherapy 21: 32, 1998.
22. Rees W, Bender J, Teague TK, Kedl RM, Crawford F, Marrack P, Kappler J. An inverse relationship between T-cell receptor affinity and antigen dose during CD4(+) T-cell responses in vivo and in vitro. Proceedings of the National Academy of Sciences USA 96: 9781, 1999.
23. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proceedings of the National Academy of Sciences USA 93: 4102, 1996.